Lunai Bioworks (LNAI) Convertible Debt (2016 - 2026)

Lunai Bioworks (LNAI) posted quarterly Convertible Debt of $120000.0 for Q1 2026, down 87.74% quarter-over-quarter from $978495.0 in Q4 2025.

Lunai Bioworks (LNAI) Convertible Debt (2016 - 2026) Analysis & Trends

Lunai Bioworks' Convertible Debt history runs 9 years deep, the most recent figure standing at $120000.0 for Q1 2026.

In Q1 2026, Convertible Debt changed N/A year-over-year to $120000.0; the TTM figure through Mar 2026 stood at $120000.0 (changed N/A YoY), while the FY2025 annual figure was $245000.0, changed 0.0% from the prior year.
Convertible Debt for Q1 2026 stood at $120000.0, down from $978495.0 in the prior quarter.
The five-year high for Convertible Debt was $3.7 million in Q1 2024, with the low at $120000.0 in Q1 2026.
The 5-year median for Convertible Debt is $1.2 million (2022), against an average of $1.1 million.
The sharpest annual moves came in 2023 and 2024: Convertible Debt slumped 37.27% in 2023, then surged 208.39% in 2024.
Lunai Bioworks' Convertible Debt stood at $1.2 million in 2022, then jumped by 114.11% to $2.6 million in 2023, then slumped by 90.46% to $245000.0 in 2024, then surged by 299.39% to $978495.0 in 2025, then plunged by 87.74% to $120000.0 in 2026.
Business Quant data shows LNAI's Convertible Debt at $120000.0 in Q1 2026, $978495.0 in Q4 2025, and $245000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Lunai Bioworks	6.87 Mn	3.72 Mn	20,942.00

Download Data